advertisement
Page 1 of 12 12311 ... LastLast
Results 1 to 10 of 112

Thread: Rumors-Possible Bad News for the Navigator :(

  1. #1

    Default Rumors-Possible Bad News for the Navigator :(

    Subject: Hello Aviator, Goodbye Navigator



    April 21, 2009
    Hello Aviator, Goodbye Navigator

    Diabetic Investor has learned that Abbott (NYSE:ABT) has decided to enter the insulin pump market and officially launch their Aviator insulin pump. Additionally, it appears the company is abandoning the Navigator as they have dramatically cut the Navigator sales force and reassigned its clinical team to other projects.

    While details are sketchy as to exactly when the Aviator will be officially launched, Diabetic Investor expects to see something at the upcoming ADA conference this June. The more important question is; Why Abbott is even entering the insulin pump market. As Diabetic Investor has been reporting for sometime the competition has intensified to such a point that even companies with a good product can?t survive. Did Abbott management learn nothing from Smiths Medical recent decision to exit the insulin pump market entirely?

    The decision to dramatically scale back Navigator sales is hardly shocking given the units dismal performance. Once the most anticipated continuous glucose monitoring system, Navigator has been a colossal disaster every since the day when Abbott foolishly sought a replacement indication from the FDA rather than an approval as an adjunct device, like everyone else in CGM did. Last to the market, the Navigator faced stiff competition from Dexcom (NASDAQXCM) and Medtronic (NYSE:MDT). The low hanging fruit already picked from the tree Abbott had the almost impossible task of coming to market with a product that was already technologically inferior and in a move only Abbot would do, priced higher than the competition. Even worse once on the market the product performed poorly as patients complained about numerous sensor failures and the devices 10 hour calibration period.

    The fact is Navigator is a classic example of a product that was designed by engineers who lacked real world market experience. As one Diabetic Investor source stated; ?The Navigator is an excellent device the only problem is they (Abbott) designed the product without thinking that one day they would have to scale up and actually make thousands of sensors.? Put another way, when you?re conducting clinical trials you can get away with making sensors by hand. Once approved you have to be able to manufacturer efficiently. Abbott management let the engineers run the show and paid little attention to what would happen if the device actually made into the market.

    Apparently the factor driving both moves is that Abbott believes that by entering the insulin pump business and scaling back Navigator will drive sales glucose test strips. Just how this will happen is anyone?s guess but as crazy as that sounds that?s the reason for these moves.

    Diabetic Investor didn?t think it was possible that Abbott could provide us with even more reasons to show just how clueless they are when it comes to the diabetes device market. It wasn?t enough that after acquiring Therasense they demoralized their employees to the point where they had no choice but to seek employment elsewhere as they just couldn?t stand it as Abbott effectively ran their once thriving company into the ground. Things became so bad at the company that they couldn?t even get a simple glucose monitor through the FDA without somehow screwing things up.

    For the moment Roche should feel comfortable that at least in one area they have not gained ground and remain firmly in second place when it comes to clueless management of diabetes devices. Roche has plenty of blunders of their own but Abbott continues to excel at making out and out dumb decisions when it comes to diabetes devices.

    You can view the email alert online by logging into your account at http://www.diabeticinvestor.com

    David Kliff
    Publisher
    Diabetic Investor
    www.diabeticinvestor.com
    www.davesrunfordiabetes.blogspot.com
    847-634-4777
    800-783-3712
    847-634-4646 fax
    224-715-3761 mobile

  2. #2

    Default

    I'm so disappointed to hear this and was truly looking forward to the next generation of the Navigator. While Kliff diminishes the engineers in the article, the engineers of the Navigator and other Therasense products are brilliant and visionary in my opinion. I have written to one of them hoping to get some type of confirmation.

  3. #3

    Default

    Quote Originally Posted by Ellen View Post
    I'm so disappointed to hear this and was truly looking forward to the next generation of the Navigator. While Kliff diminishes the engineers in the article, the engineers of the Navigator and other Therasense products are brilliant and visionary in my opinion. I have written to one of them hoping to get some type of confirmation.
    As an engineering student, I beg to differ on the quality of the device. I believe that the design and the quality of the actual device has possibly led to this product's demise.

    Although there were some brilliant people, particularly engineers, that were involved with the chemistry of the sensors and the calibration algorithm, which made it very accurate-the design of the device ruined it's reputation.

    I don't think the engineers are at fault here. I don't think that they are necessarily incompetent, as Kliff states. The management is at fault for not monitoring the situation, and addressing quality control concerns in the first place. This includes even prior to market approval. Abbott knew that the device had issues even before it reached the public, too. If you have been reading posts on this forum regarding the Navigator, you can tell that the management and many other individuals kind of do their own thing within this company, and do not work together. It's blatantly obvious, imo.

    Very few of the quality control issues (stemming from the design of the product) were ever properly addressed and/or resolved by Abbott.

    Believe me, I am sad and disappointed about this situation. But with all of the problems I have experienced with this device, I am not surprised at all.
    Last edited by moco89; 04-25-2009 at 03:41 PM.

  4. #4

    Default

    Based on the information presented, it doesn't make sense that this is an engineering problem. Engineers live and die by "pairs and eaches," and it seems unlikely they would make this kind of error. This sounds to me like a misallocation of resources or lack of foresight than engineering problems.
    Type 1 Diabetic since 2001. Minimed 722 with Novolog and CGMS.

    Dad of Emma, age 9, diagnosed at 9 months pumping with MM REVEL CGMS and Novolog. She also has been diagnosed with Hashimoto's Disease, Juvenile Rheumatoid Arthritis, Glomerular Nephritis, Multiple-Autoimmune Complex, along with lots of other stuff that makes doctors shrug and say "I dunno."

    Brenden, aka "Rhino" age 14. Starting tailback for Clovis Freshman Academy (had to say it).

    Husband of Emmasmom.
    www.toosweetboutique.net

  5. #5
    Join Date
    Nov 2007
    Location
    Hastings, MN
    Posts
    3,803

    Default

    Thanks for posting this Monica.

    I just pasted this into an email and sent it to the diabetes educator who has been helping us in our quest to get Jacob a CGM. His endo has recommended the Navigator and almost no one at this clinic uses the Dexcom. I asked her to forward this info to Jacob's endo.
    Dave (non D)
    Single father of Jacob (Type 1, dx'd 11/2005, born 12/11/2000)
    Medtronic Revel 722 since 1/08/2012; Apidra
    AccuCheck Aviva meter, Sure T infusion set
    Guardian CGM since 1/9/2012
    Former Animas and Dexcom user
    Father of Andrea, 15 and Logan, 18 (all non D)


    "Consistency is the last refuge of the unimaginative." - Oscar Wilde
    "Progress is made by lazy men looking for easier ways to do things." - Robert A. Heinlein

  6. #6

    Default

    I don't subscribe to Kliff's investor newsletter (can't afford it either), but can anyone here share an opinion about Kliff's general level of accuracy with respect to items like this?

  7. #7
    Join Date
    Nov 2007
    Location
    Hastings, MN
    Posts
    3,803

    Default

    As far as the quality:

    I am a prototype machinist by trade. ALL products are first made by prototype. This is 100% different then making them in production. Making 10 is also far different than making 1000. On top of that, something that works great for a month is far different than something that works great for two years.
    Not only does each individual product have to have 100% quality and last over time, the machines THAT MAKE THEM have to work flawlessly as well and those machines have to last.

    Technology doesn't matter either if you wrap that technology in junk.
    Dave (non D)
    Single father of Jacob (Type 1, dx'd 11/2005, born 12/11/2000)
    Medtronic Revel 722 since 1/08/2012; Apidra
    AccuCheck Aviva meter, Sure T infusion set
    Guardian CGM since 1/9/2012
    Former Animas and Dexcom user
    Father of Andrea, 15 and Logan, 18 (all non D)


    "Consistency is the last refuge of the unimaginative." - Oscar Wilde
    "Progress is made by lazy men looking for easier ways to do things." - Robert A. Heinlein

  8. #8

    Default

    Also wondering - what would it look like to a potential buyer of a first generation Aviator pump on the market from a company that is now abandoning another first generation product around which there was so much hype and enthusiasm? Hard to imagine Abbott would make that decision now.
    Last edited by Ellen; 04-25-2009 at 06:51 PM.

  9. #9

    Default

    Quote Originally Posted by Ellen View Post
    I don't subscribe to Kliff's investor newsletter (can't afford it either), but can anyone here share an opinion about Kliff's general level of accuracy with respect to items like this?
    I can't confirm his accuracy, but a close friend of mine has a subscription to his material.

    The freelance journalist Amy T refers to his reports a lot, so his reports are at least somewhat credible-as far as I can tell. Here's a search of "Kliff" on her blog. http://www.diabetesmine.com/?s=kliff

  10. #10
    Join Date
    Mar 2008
    Location
    Colorado
    Posts
    4,265

    Default

    Quote Originally Posted by Ellen View Post
    I don't subscribe to Kliff's investor newsletter (can't afford it either), but can anyone here share an opinion about Kliff's general level of accuracy with respect to items like this?
    I think we all should have learned by now that stock analysts can be totally full of it. You also need to know what is influencing them to trash a company like this.

    As far as I know, Abbott is in clinical trials right now for 1 hour startup. And their product is not technologically inferior. That's a bunch of nonsense. They out-perform the other CGMs. They have issues with quality control and stocking.

    There's some ulterior motive behind this analysis, because it's not accurate in the details. He could just be trying to manipulate the stock price.

    Rella, mom to Brendan -- 14-yrs-old, dx'd March '08 at 8 years old
    Navigator CGM: 11/08 to 1/11
    Dexcom CGM since 2/11, G4 as of 10/12
    OmniPod since 7/09


    Help Cure Childhood Diabetes
    Facebook


Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •